REGN P/B: current value, 10-year range and year-by-year history
Cash & Leverage
REGN's p/b is lower than 83% of the last 10 years.
P/B History
REGN P/B by year
Yearly range of REGN’s p/b from 2016 to 2026. Over the full period it ranged from 1.8 to 12.5, averaging 4.9.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 2.1 | 2.5 | 2.9 | 2.6 |
| 2025 | 1.8 | 2.3 | 2.9 | 2.7 |
| 2024 | 2.8 | 4.0 | 4.9 | 2.8 |
| 2023 | 3.3 | 3.8 | 4.2 | 4.0 |
| 2022 | 3.1 | 3.7 | 4.2 | 3.8 |
| 2021 | 3.6 | 4.5 | 5.6 | 3.8 |
| 2020 | 3.5 | 5.9 | 8.6 | 4.9 |
| 2019 | 3.0 | 4.1 | 5.8 | 3.9 |
| 2018 | 4.9 | 5.9 | 7.4 | 4.9 |
| 2017 | 6.9 | 9.5 | 12.5 | 7.3 |
| 2016 | 8.7 | 10.2 | 12.0 | 9.5 |
Get notified when REGN P/B crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
How much the market pays relative to the company's accounting net worth (assets minus liabilities). P/B < 1 means the market values the company below what the books say it owns.
Price / Book Value Per ShareMost useful for asset-heavy businesses: banks, insurers, REITs. A P/B near its historical low suggests the market is paying unusually little for the net assets.
- Goodwill and intangibles from acquisitions can inflate book value significantly — some analysts prefer tangible book value.
- Low P/B in technology or software companies is usually irrelevant: their value is in IP and people, not balance sheet assets.
Is REGN P/B High or Low Right Now?
Regeneron Pharmaceuticals, Inc.'s P/B is currently 2.6, which is historically cheap relative to its 10-year historical range. The 10-year median P/B for REGN is approximately 4.1. See all REGN valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.